Chinese General Hospital unveils upgraded nuclear facility
CGHMC doctors and PCCAI board members gather at the hospital’s new NM/CT 860 SPECT/CT machine, one of only two in the country.
Photo courtesy of CGHMC
Text size
CGHMC doctors and PCCAI board members gather at the hospital’s new NM/CT 860 SPECT/CT machine, one of only two in the country.
Photo courtesy of CGHMC
Buddies, associates? One happy family?
A traditional dish called zongzi is served during China’s Dragon Boat Festival, which falls in June. It is a rice…
Divina credited the firm’s achievements to its members, thanking them for their ‘hard work, dedication, teamwork, and…
‘Sec. Vince Dizon, please explain how this finding of your own team should not be flagged as a ghost project in Taguig.’
Chinese General Hospital and Medical Center (CGHMC) - Department of Nuclear Medicine unveiled its newly upgraded nuclear facility, marking a significant milestone for the hospital.
In his welcome remarks, CGHMC President and CEO Dr. Kelly Sia said that this expanded nuclear medicine facility now accommodates state-of-the-art equipment and provides a more comfortable area to enhance the patient experience.
“CGHMC is making significant strides in medical advancements, incorporating cutting-edge technologies and using innovative approaches for different specializations,” he said.
Meanwhile, CGHMC Medical Director Dr. Samuel Ang credited the support of the hospital leadership and the Philippine Chinese Charitable Association, Inc. (PCCAI) for this milestone in the Nuclear Department, including the acquisition of one of only two SPECT CT 860 machines in the Philippines.
“Our hospital remains at the forefront in the treatment of cancer and heart disease, and the Nuclear Department is a vital component in the fight against these diseases,” Ang said.
The enhanced facility showcases the department’s newest acquisitions, state-of-the-art technologies such as the Gamma Probe and the SPECT Hybrid System, which elevate the precision and efficacy of diagnostic imaging and surgical localization.
One of the highlights of the facility’s advanced offerings is the integration of Lutetium-177-based therapies, a cutting-edge molecular treatment that harnesses theranostic principles to target specific cancer cells while minimizing damage to healthy tissue.
This therapy is especially promising for patients with neuroendocrine tumors and prostate cancer, offering new hope through evidence-based, personalized care.
Sia stressed that the expansion "paves the way for accuracy in diagnoses, targeted treatments, and precise medical interventions."
“This is just one of the many advanced diagnostic and therapeutic capabilities in our Nuclear Medicine Department that contribute to advanced patient care," he continued.
"What’s more, this opens doors and opportunities for collaboration with other specializations or healthcare institutions, as well as further education and training in this field,” he added.
